Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible ...

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Johnson & Johnson has reported Phase III data where CARVYKTI improved overall survival in patients with multiple myeloma.

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced the CHMP of the European Medicines Agency has recommended the ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & ...